Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

被引：31
|
作者：
Janne, Pasi A.
Baik, Christina S.
Su, Wu-Chou
Johnson, Melissa Lynne
Hayashi, Hidetoshi
Nishio, Makoto
Kim, Dong-Wan
Koczywas, Marianna
Gold, Kathryn A.
Steuer, Conor Ernst
Murakami, Haruyasu
Yang, James Chih-Hsin
Kim, Sang-We
Vigliotti, Michele
Qi, Zhenhao
Qiu, Yang
Zhao, Lihui
Sternberg, David W.
Yu, Channing
Yu, Helena Alexandra
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[4] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[5] Kindai Univ Hosp, Osaka, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[7] Seoul Natl Univ Hosp, Seoul, South Korea
[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[9] Univ Calif San Diego, San Diego, CA 92103 USA
[10] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[11] Shizuoka Canc Ctr, Shizuoka, Japan
[12] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[13] Univ Ulsan, Coll Med, Seoul, South Korea
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9007
引用
收藏
页数：3
相关论文
共 50 条
  • [11] HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
    Janne, Pasi A.
    Johnson, Melissa L.
    Goto, Yasushi
    Yang, James Chih-Hsin
    Vigliotti, Michele
    Dong, Qian
    Qiu, Yang
    Yu, Channing
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [12] Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC
    Janne, Pasi A.
    Mostillo, Joseph
    Shrestha, Pomy
    Zhang, Ruoyang
    Fan, Pang-Dian
    Cantero, Frederique
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [13] EGFR inhibitor upregulates HER3 expression and enhances the efficacy of HER3 targeting patritumab deruxtecan (HER3-DXd)
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Sakai, Kazuko
    Goto, Hiroki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Otsuka, Eri
    Okida, Hiroaki
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2022, 113 : 896 - 896
  • [14] Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC
    Janne, P.
    Rajagopalan, R.
    Pudussery, G.
    Shrestha, P.
    Chen, S.
    Hodge, R.
    Qiu, Y.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
  • [15] HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
    Janne, P.
    Johnson, M.
    Goto, Y.
    Yang, J. C.
    Karam, S.
    Chen, S.
    Qiu, Y.
    Yu, H.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S236 - S236
  • [16] HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
    Yonesaka, Kimio
    Tanizak, Junko
    Maenishi, Osamu
    Haratani, Koji
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Chiba, Yasutaka
    Tsuya, Asuka
    Goto, Hiroki
    Otsuka, Eri
    Okida, Hiroaki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2022, 28 (02) : 390 - 403
  • [17] Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
    Yu, H. A.
    Baik, C. S.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W-C.
    Yang, J.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1189 - S1190
  • [18] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [19] Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
    Hayashi, Hidetoshi
    Yu, Helena A.
    Baik, Christina
    Gold, Kathryn
    Johnson, Melissa L.
    Koczywas, Marianna
    Murakami, Haruyasu
    Nishio, Makoto
    Steuer, Conor
    Su, Wu-Chou
    Yang, James C. H.
    Karam, Samer
    Qui, Zhenhao
    Qiu, Yang
    Chen, Shuquan
    Yu, Channing
    Janne, Pasi A.
    ANNALS OF ONCOLOGY, 2021, 32 : S318 - S318
  • [20] Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Haratani, Koji
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Chiba, Yasutaka
    Goto, Hiroki
    Otsuka, Eri
    Okida, Hiroaki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345